A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

NCT03660878 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Conjunctivitis

Interventions

DRUG: Reproxalap Ophthalmic Solution (0.25%)
DRUG: Reproxalap Ophthalmic Solution (0.5%)
DRUG: Vehicle Ophthalmic Solution

Sponsor

Aldeyra Therapeutics, Inc.